8月11日，映恩生物-B盘中上涨5.28%，报205.4港元，成交额1.03亿港元。该股此前因GSK竞争压力于7月30日大跌后持续修复，本次上涨主要受生物科技板块集体走强带动。
消息面上，同行业个股今日普涨，百济神州涨4.41%、再鼎医药涨4.6%、康方生物涨2.76%，板块情绪延续回暖。基本面方面，公司科创板IPO申请已进入"已问询"阶段，拟募资41亿元；核心管线B7-H3 ADC此前获NMPA突破性疗法认定；中国银河、东吴证券等多家机构近期首次覆盖给予"买入/推荐"评级，目标价418.61港元，多重利好持续支撑估值修复。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.